首页> 外文期刊>Journal of Medicinal Chemistry >Improving the Odds of Success in Drug Discovery: Choosing the Best Compounds for in Vivo Toxicology Studies
【24h】

Improving the Odds of Success in Drug Discovery: Choosing the Best Compounds for in Vivo Toxicology Studies

机译:改善药物发现成功的几率:为体内毒理学研究选择最佳化合物

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

A set of molecules that advanced into exploratory animal toxicology studies (two species) was examined to determine what properties contributed to success in these safety studies. Compounds were rigorously evaluated across numerous safety end points and classified as "pass" if a suitable in vivo therapeutic index (TI) was achieved for advancement into regulatory toxicology studies. The most predictive end point contributing to compound survival was a predicted human efficacious concentration (C_(eff)) of ≤250 nM (total drug) and ≤40 nM (free drug). This trend held across a wide range of CNS modes of action, encompassing targets such as enzymes, G-protein-coupled receptors, ion channels, and transporters.
机译:检查了一组进入探索性动物毒理学研究的分子(两种),以确定哪些性质有助于这些安全性研究的成功。如果实现了适合的体内治疗指数(TI)进入监管毒理学研究,则对化合物在多个安全终点上进行严格评估,并归类为“合格”。有助于化合物存活的最可预测的终点是预测的人体有效浓度(C_(eff))≤250nM(总药物)和≤40nM(游离药物)。这种趋势在广泛的CNS作用模式中保持,包括酶,G蛋白偶联受体,离子通道和转运蛋白等靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号